[Use of Falicard and Sectral in patients with COPD and ischemic heart disease].
Thirty patients with chronic obstructive pulmonary disease (ChOPD) and concomitant ischemic heart disease (IHD) were studied that were admitted to the clinic for the treatment of a recurrence of the basic disease within the period 1981-1982. The patients were grouped into three groups of 10 patients and each group was treated for a period of 14 days, as follows: group 1--10 patients were given only sectral 50 mg per os during the first week and 10 mg/day during the second week; group II--treated with falicard, 5 mg daily, intravenously, for one week and later 2 X 5 mg, intravenously--the second week; group III, received sectral--50-100 mg/day after 5 mg falicard intravenously. Best results, manifested with a reduction of the paroxysms of dyspnea and stenocardia, were obtained in group III, suggesting the advantage of the combined effect with cardioselective beta-blockers and Ca-antagonists in the patients with ChOPD and concomitant IHD.
D000787:Angina Pectoris / Q000188:drug therapy; D001262:Atenolol / Q000008:administration & dosage / Q000627:therapeutic use*; D003327:Coronary Disease / Q000188:drug therapy*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000188:drug therapy*; D014700:Verapamil / Q000008:administration & dosage / Q000627:therapeutic use*
D001262:Atenolol; D014700:Verapamil
Prilozhenie na Falicard i Sectral pri bolni s KhOBB i IBS.